Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:12/11/2007

Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
11. Phase III Trial Finds Pharmaxis Bronchitol Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... ... studies at the International Spine Intervention Society’ s 23rd Annual Scientific ... August 1st, 2015. With a focus on evidence-based research and clinical application, the ...
(Date:8/28/2015)... , Aug. 28, 2015 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of ... the quarter ended June 30, 2015, corporate highlights, ... management report are available at www.sedar.com ,  ... "RepliCel expects to launch its ...
(Date:8/28/2015)... Brooklyn, NY (PRWEB) , ... August 28, 2015 , ... Since the initial launch of ... with their quirky humor and excellent customer service. Images such as the Fonz in ... website to add some flavor to the humdrum spectroscopy field. , FireflySci is ...
(Date:8/27/2015)... Reston, VA (PRWEB) , ... August 27, 2015 , ... ... government contractors solve complex business problems, is pleased to announce their ranking as one ... 34th annual ranking of the fastest-growing private companies across the nation. , “It is ...
Breaking Biology Technology:Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3
... Mass., Sept. 28 Decision Resources, one of the ... healthcare issues finds that, owing to increasing generic availability ... from $26 billion in 2009 to $23 billion in ... United Kingdom and Japan. The Pharmacor 2010 ...
... 2010 ... ... var shortURL = ""; ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; ...
... SHENZHEN, China, Sept. 28 /PRNewswire-Asia-FirstCall/ -- ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
Cached Biology Technology:Due to Generic Erosion, the Hypertension Drug Market Will Decline by $3 Billion from 2009 to 2019 2Pepscan Therapeutics Announces Establishment of Scientific Advisory Board 2Pepscan Therapeutics Announces Establishment of Scientific Advisory Board 3Pepscan Therapeutics Announces Establishment of Scientific Advisory Board 4Pepscan Therapeutics Announces Establishment of Scientific Advisory Board 5Pepscan Therapeutics Announces Establishment of Scientific Advisory Board 6Pepscan Therapeutics Announces Establishment of Scientific Advisory Board 7Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 2Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 3Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 4Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 5Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 6Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 7Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 8
(Date:8/4/2015)... ) today reported financial and operating results for the second quarter ... quarter contract revenue of $ 85.2 million, a ... of 26 % , Second quarter adjusted ... royalties in the current quarter , Operating cash ... to present another strong financial quarter, with all our divisions achieving ...
(Date:7/31/2015)... 2015 A 10 a. Conferência Internacional ... BGI de 22-25 de outubro de 2015, em ... está celebrando seu 10 o. aniversário este ano. Desde ... das reuniões mais influentes do mundo no ramo das ... e prazerosos. A ICG-10 se concentra ...
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... a specific mutation in a gene in horses that affects ... related to racing performance and is advantageous for harness-racing horses. ... on their diversification, as the altered gait characteristics of a ... study that includes a Texas A&M University researcher. Gus ...
... roofs or in sun-drenched fields, quietly harvesting the sun,s ... green energy movement. But could they be better ... Drexel University and The University of Pennsylvania are trying ... nanotechnology and a lot of mathematical modeling. ...
... A new center at the University of Michigan will ... development at laboratories across campus. , Called the Center ... coordinate and support work in a range of departments ... the translation of early research toward patient usea gray ...
Cached Biology News:Controlling gait of horses may be possible, says key study from Texas A&M 2Soaking up the Sun 2Soaking up the Sun 3Soaking up the Sun 4Chemicals today, drugs tomorrow: U-M's new Center for Drug Discovery 2Chemicals today, drugs tomorrow: U-M's new Center for Drug Discovery 3